Analyzing Craneware (OTCMKTS:CRWRF) & Forian (NASDAQ:FORA)

Craneware (OTCMKTS:CRWRF) and Forian (NASDAQ:FORA) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares Craneware and Forian’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Craneware	N/A	N/A	N/A
Forian	N/A	N/A	N/A

Earnings and Valuation

This table compares Craneware and Forian”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Craneware	N/A	N/A	N/A	$0.32	87.70
Forian	$19.71 million	3.26	-$2.79 million	($0.09)	-23.00

Craneware has higher earnings, but lower revenue than Forian. Forian is trading at a lower price-to-earnings ratio than Craneware, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Craneware and Forian, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Craneware	0	0	0	0	0.00
Forian	0	0	1	0	3.00

Forian has a consensus target price of $5.00, suggesting a potential upside of 141.55%. Given Forian’s stronger consensus rating and higher possible upside, analysts clearly believe Forian is more favorable than Craneware.

Insider & Institutional Ownership

48.2% of Craneware shares are held by institutional investors. Comparatively, 19.3% of Forian shares are held by institutional investors. 31.3% of Forian shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Forian beats Craneware on 5 of the 8 factors compared between the two stocks.

About Craneware

Craneware plc, together with its subsidiaries, develops, licenses, and supports computer software for the healthcare industry in the United States. The company provides solutions, such as Trisus pricing transparency software; Trisus Pricing Analyzer, a solution that simplifies and automates the price modeling process; Trisus Chargemaster, an automated chargemaster management solution; InSight Medical Necessity, a solution that offers medical necessity for the United States payors; Trisus Claims Informatics, a retrospective charge capture analytical application that identifies areas of risk for its team to investigate; Trisus Supply, a solution that improves supplies reimbursement; and InSight Audit, an audit management solution for government and commercial payors. It also offers Trisus Decision Support; Trisus Labor Productivity; Trisus Medication Analytic solutions; and Trisus supplies assistant solutions. In addition, the company provides Sentinel, a drug tracking solution; Sentrex, a SaaS-based solution that helps covered entities expand medication access; Referral Verification System; and Central Pharmacy Distribution, a centralized purchasing application. Further, it offers appeal, professional, and pharmacy professional services. Craneware plc was incorporated in 1999 and is headquartered in Edinburgh, the United Kingdom.

About Forian

Forian Inc. provides a suite of data management capabilities, and information and analytics solutions to optimize and measure operational, clinical, and financial performance for customers in the healthcare and related industries. It develops commercial, real world evidence (RWE), and market access solutions and proprietary data-driven insights, as well as offers data management solutions. The company’s subscription and services-based solutions cover the life sciences, pharma services, and healthcare payer and provider industries. Forian Inc. was founded in 2020 and is headquartered in Newtown, Pennsylvania.